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NEUROLOGICAL DIESEASES/DISORDERS &
PAIN—Economic Outcomes
PNP1
CHOLINESTERASE INHIBITORS REDUCE
INSTITUTIONALIZATION RISK AND MAY
REDUCE OVERALL ECONOMIC BURDEN FOR
PATIENTS WITH DEMENTIA IN A
NATURALISTIC TREATMENT SETTING
Luong D1, Sambrook R2,Yu A2, COSID Investigators3
1Janssen Ortho Inc,Toronto, ON, Canada; 2Syreon
Corporation,Vancouver, BC, Canada; 3Canada
OBJECTIVE: Cholinesterase inhibitors have been shown
to delay institutionalization, thus reducing costs. Institu-
tionalization rates, direct, indirect and drug costs were
examined in the Canadian Outcomes Study in Dementia
(COSID); an ongoing observational cohort study of 
clinical and economic outcomes for dementia patients 
in Canada. METHODS: A Cox Proportional Hazards
regression model compared institutionalization rates be-
tween patients receiving (ChI) or not receiving choline-
sterase inhibitors (non-ChI) at the time of enrolment (n =
448). A linear regression model also compared direct out-
patient and inpatient costs (e.g. hospitalisations, commu-
nity services, day surgery), indirect costs (lost caregiver
and patient productivity) and drug costs (including and
excluding ChI costs) in the ChI and non-ChI groups. Both
models adjusted for dementia type, place of residence,
disease duration, baseline Global Deterioration Stage and
Caregiver Burden (ZBI), age and gender. Follow-up was
from baseline to last visit date (between 6 and 18
months). RESULTS: This model-based assessment shows
strong evidence that treatment with ChIs is associated
with reduced institutionalization risk (RR = 0.262, p =
.0032). Because most patients were lost to follow-up on
or shortly after institutionalization, this analysis does not
account for the cost of institutionalization. However,
reducing the rate of institutionalization almost certainly
yields signiﬁcant cost savings. Other signiﬁcant predictors
of risk include baseline ZBI (RR = 1.033 per point, p =
.0394) and age (RR = 1.107 per year, p = .0085). The
linear regression model for costs demonstrated no signif-
icant differences in inpatient (excluding institutionaliza-
tion), indirect and overall costs between non-ChI and ChI
patients. Drug costs were estimated to be $134 per month
greater for the ChI group than the non-ChI group ($168
vs $34, p < .0001). CONCLUSIONS: The use of ChIs
appeared to have a signiﬁcant effect on institutionaliza-
tion rates and drug costs, but not on other cost drivers in
this disease. The reduced rate of institutionalization likely
translates into cost savings for the ChI treatment strategy.
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ECONOMIC IMPACT OF TREATMENT OF
DEMENTIA FOR GERMANY—A PROGNOSIS 
TO 2050
Happich MV1, Hallauer J2
1Technical University, Berlin, Germany; 2Charité, University
Hospital, Berlin, Germany
OBJECTIVE: To assess the development of costs for
dementia in Germany until 2050 under different demo-
graphic scenarios and the possible impact of treatment
interventions with acethylcholinesterase inhibitors from
various perspectives. METHODS: A model to estimate
cost differences in dementia treatment with acethyl-
cholinesterase inhibitors compared to a placebo scenario
was developed. The model projects the number of demen-
tia patients in Germany until 2050 under the assumption
of extended life expectancy and immigration. Markov
modeling allows documenting the progression of demen-
tia patients into more severe disease stages. Data of 
the population development are supplied by the Federal
Bureau of Statistics and the German Institute for Eco-
nomic Research. Number of patients are calculated from
demographic prognoses considering prevalence of disease
data from a published metaanalyses of the epidemiology
of dementia. Data about transition probabilities between
different disease stages are derived from a randomized
clinical trial of an acethycholinesterase drug. Disease
stage speciﬁc costs are taken from a cost of illness study
previously published. RESULTS: The number of demen-
tia patients will increase from 1 million to 2.5 million
over the next 50 years in Germany. With treatment, there
will be 30% less patients in the most severe, and hence
most costly disease stage. Costs for treatment are offset
by cost savings through a shift of patients to less severe
disease stages, if indirect family and caring costs are con-
sidered. Reduction of direct costs due to treatment
increase from €0.5 to €1.5 billion and indirect cost reduc-
tions are fourfold these ﬁgures. For 2000, net savings of
€1.4 billion are demonstrated for the societal perspective.
Results are stable for extensive sensitivity analysis. CON-
CLUSION: Results document that dementia treatment is
economically attractive in an aging society.
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OBJECTIVES: Surveys based on patient registries in
headache clinics have concluded that a signiﬁcant 
proportion of headache sufferers have chronic daily
headaches (CDH). However, there is as yet no informa-
tion on the socio-economic impact of CDH in the general
population. To address this shortcoming, we have con-
ducted this study. METHODS: We have exploited the
data obtained in a recent large, nationwide study of the
clinical epidemiology of headache disorders performed 
in France (GRIM-2000). This study screened 10585 sub-
jects, representative of the total French population, and
involved face-to-face interview with 1486 subjects iden-
tiﬁed as suffering from headaches. A positive reply to
question “Do you suffer from headaches every day?” led
to a diagnosis of CDH. As well as collecting epidemio-
logical data, this study also assessed data on the clinical
presentation, quality of life, disability, and healthcare
consumption. Individuals with CDH were compared to
subjects with migraine as diagnosed according to IHS 
criteria. RESULTS: The prevalence of CDH in French
general population was 2.95%. Prevalence was signiﬁ-
cantly higher in females than in males. The CDH indi-
viduals were older than migraine sufferers. A signiﬁcant
degree of disability was conﬁrmed in CDH individuals
who scored worse than migraine sufferers. Individuals
with CDH also scored worse than individuals with
migraine for quality of life. Concerning the consumption
of healthcare resources, main results were that: (i) the
number of visits to GPs was signiﬁcantly greater in CDH
individuals than in migraine sufferers, (ii) psychiatrists
were the medical speciality most often consulted, (iii)
drug consumption was over six times higher in the CDH
group than in the migraine group. CONCLUSIONS: This
study indicates that CDH is associated with an important
burden of suffering in the general population and with
considerable expenditure in the health service.
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SWITCHING AND PERSISTENCY IN A NSAID
AND COX-2 SPECIFIC INHIBITOR USER
POPULATION IN MANAGED CARE
Harley C1, Wagner S2, Nelson M1
1Ingenix, Eden Prairie, MN, USA; 2Pharmacia Corporation,
Peapack, NJ, USA
OBJECTIVES: Our objectives were to examine patterns
of medication switching, treatment discontinuation, and
associated costs in subjects treated with COX-2 speciﬁc
inhibitors or non-selective NSAIDs in a managed care
setting. METHODS: We conducted a retrospective claims
analysis in 19 managed care health plans in the United
States to evaluate three cohort groups treated with cele-
coxib, rofecoxib, or commonly prescribed non-selective
NSAIDs between July 1, 1999 and June 30, 2000. Medi-
cation utilization, switching, discontinuation, and costs
associated with medication switching and discontinuation
were evaluated. We used propensity score analysis to
match cohorts to reduce possible sampling selection bias.
RESULTS: 164,596 subjects were assigned to the cele-
coxib (n = 9,475), rofecoxib (n = 7,734) or non-selective
NSAID groups (n = 147,387). COX-2 speciﬁc inhibitor
users were signiﬁcantly less likely to switch therapy (23%
less likely by odds ratio test [p < 0.001]) and had a lower
rate of discontinuation compared to NSAID users (7.2 
vs. 18.7 discontinuations per 1000). Cox proportional
hazards analysis demonstrated that persistency on
therapy is higher for COX-2 users (57% less likely to dis-
continue) versus NSAID users. Patients remained longer
on celecoxib before discontinuation compared to subjects
in any other cohort (celecoxib 63.7 days, rofecoxib 
58.9 days, ibuprofen 21.1 days, naproxen 27.8 days, 
and diclofenac 34.4 days). Age was also associated with
longer time on therapy, with older age decreasing the like-
lihood of discontinuation by 2%. Switching therapy
increased total costs by 21.9% (p < 0.01). Outpatient,
inpatient, and emergency room costs increased in subjects
who switched therapy compared to those who remained
on therapy, when COX-2 speciﬁc inhibitor and NSAID
matched cohorts were compared. CONCLUSIONS: Less
medication switching and longer persistency were seen in
patients treated with COX-2 speciﬁc inhibitors. Medica-
tion switching was associated with increased treatment
costs. The increased resource use may be ascribed to
adverse events, which may be higher in the non-selective
NSAID cohorts.
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DIRECT COSTS OF BACK PAIN IN THE UNITED
STATES:A NATIONAL ESTIMATE
Mychaskiw MA,Thomas III J
Purdue University, West Lafayette, IN, USA
OBJECTIVES: Prior studies of direct costs of back pain
have primarily used Workman’s Compensation claims,
resulting in varying cost estimates and limiting generali-
zibility of ﬁndings to speciﬁc employee groups. The objec-
tives of this study were to determine the direct costs of
back pain among the general population and to stratify
those costs by type of medical care. METHODS: Retro-
spective analysis was conducted of the 1996 Medical
Expenditure Panel Survey. The survey ﬁles included 
data collected from a nationally representative sample of
22,601 respondents and from respondents’ medical care
and health insurance providers. Data included medical
conditions, use and payments for medical care, and 
health insurance and employment information. Back pain
patients were identiﬁed using ICD-9-CM codes deter-
mined by an expert panel of physicians and coders as
indicative of back pain. Direct costs were calculated using
patient and third-party payments for back pain related
medical events by category of back pain and type of
medical care. Sample estimates were projected to the pop-
ulation and 95 percent conﬁdence limits were calculated
using the Taylor expansion method. RESULTS: The direct
